Cardiol Therapeutics files Q3 2026 MD&A, citing need for more financing as it develops heart inflammation drugs
Cardiol Therapeutics, a Canadian company developing treatments for inflammation and fibrosis in heart disease such as recurrent pericarditis, acute myocarditis and heart failure, issued its MD&A for the three and nine months ended September 30, 2026, dated November 12, 2026. The excerpt contains only the introduction and forward-looking statements and risk factors, including negative operating cash flow, a history of losses and a requirement for additional financing. It gives no financial results or clinical or regulatory updates.
Company's press release (SEC filing): Cardiol Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
